Zuyderland Medisch Centrum Stichting

The trials here

What the 62 trials at this site are about, from their registry records.

Conditions

• Idiopathic pulmonary fibrosis11 trials
• Lung cancer8 trials
• Obesity7 trials
• Stroke6 trials
• COPD5 trials
• Atrial fibrillation4 trials
• Heart failure4 trials
• Coronary artery disease3 trials
• Multiple sclerosis3 trials
• Ankylosing spondylitis2 trials
• Melanoma2 trials
• Multiple myeloma2 trials
• and 12 more

Phase

• Phase 336 trials
• Phase 413 trials
• Phase 211 trials
• Phase 2/32 trials

Status

• Recruiting21 trials
• Completed18 trials
• Active, not recruiting13 trials
• Not yet recruiting9 trials
• Suspended1 trial

Lead sponsor

• Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)4 trials
• AstraZeneca3 trials
• Chiesi Farmaceutici S.p.A.3 trials
• Merck Sharp & Dohme LLC3 trials
• Novo Nordisk A/S3 trials
• and 40 more

Running trials

• Not yet recruiting

  Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

  NCT07441408· Phase 3· Bristol-Myers Squibb· Source

• Not yet recruiting

  A Phase 2 trial of AGMB-447 in participants with idiopathic pulmonary fibrosis

  2026-526404-71-00· Phase 2· Agomab Spain S.L.U.· Source

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Phase IIb Study to Evaluate AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

  2025-525016-41-00· Phase 2· AstraZeneca AB· Source

• Recruiting

  ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3

  NCT06716021· Phase 3· Milestone Pharmaceuticals Inc.· Source

• Recruiting

  Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

  NCT07626411· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

  NCT07725939· Phase 2· UCB Biopharma SRL· Source

• Recruiting

  A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis

  NCT07516951· Phase 2· Chiesi Farmaceutici S.p.A.· Source

• Recruiting

  Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)

  NCT07284602· Phase 3· PureTech· Source

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Novo Nordisk A/S· Source

• Not yet recruiting

  Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy

  NCT07486687· Phase 3· The Netherlands Cancer Institute· Source

• Recruiting

  Neoadjuvant FOLFOXIRI and Chemoradiotherapy versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy, followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer

  NCT07472868· Phase 3· Catharina Ziekenhuis Stichting· Source

• Recruiting

  Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

  NCT07284459· Phase 2· Contineum Therapeutics· Source

• Recruiting

  A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)

  NCT07276724· Phase 3· Generate Biomedicines· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)

  2024-516654-22-00· Phase 3· Amgen Inc.· Source

• Active, not recruiting

  A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)

  NCT07133633· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer

  2024-515884-69-00· Phase 3· Gilead Sciences Inc.· Source

• Recruiting

  A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy

  NCT06979375· Phase 2· Novo Nordisk A/S· Source

• Recruiting

  StAtins in Frail oldEr patients with ischemic Stroke or Transient ischemic attack – The Randomized Controlled Trial

  2024-517343-31-00· Phase 4· Amsterdam UMC Stichting· Source

• Recruiting

  Semaglutide 2.4mg for low responders after bariatric surgery

  2022-502164-20-01· Phase 4· Stichting Zuyderland Medisch Centrum· Source

• Active, not recruiting

  Multi-institutional Evaluation of the Cost-effectiveness of PSMA-PET/CT for the Detection of Pelvic Lymph Node Invasion in Newly Diagnosed Prostate Cancer Patients (PSMA-SELECT).

  2024-518171-59-00· Phase 4· Canisius Wilhelmina Ziekenhuis· Source

• Recruiting

  Safe Stop Trial Melanoma

  2024-516937-10-01· Phase 3· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source

• Recruiting

  Stopping or continuing blood thinners after stroke at young age without a known cause: STOP trial

  2024-513092-40-00· Phase 4· Stichting Radboud universitair medisch centrum· Source

• Recruiting

  The PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis – A randomized controlled trial

  2024-514055-15-00· Phase 4· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source

• Recruiting

  Perioperative SDD to Prevent Infectious Complications After Esophagectomy

  NCT05865743· Phase 3· Radboud University Medical Center· Source

• Recruiting

  A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

  NCT06561386· Phase 3· Bristol-Myers Squibb· Source

• Active, not recruiting

  A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  NCT06238622· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  Safe Stop ipi-nivo

  2024-516938-34-00· Phase 3· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source

• Active, not recruiting

  DUTCH Weight Control in Atrial Fibrillation Study

  NCT06184633· Phase 4· Rijnstate Hospital· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis

  2023-503699-25-00· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis

  2023-503697-21-01· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source

• Active, not recruiting

  Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

  NCT06236438· Phase 2/3· AbbVie· Source

• Recruiting

  Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

  NCT06136624· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

  NCT06141486· Phase 3· Sanofi· Source

• Active, not recruiting

  Noisy Rebels; Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS

  2022-502664-21-00· Phase 4· Amsterdam UMC· Source

• Recruiting

  Peroperative Administration of Tranexamic acid in gastric bypass to reduce haemorrhage in patients with morbid obesity

  NCT05464394· Phase 3· Sint Franciscus Vlietland Groep Stichting· Source

• Not yet recruiting

  Applying Mysimba in patients with weight regain after bariatric surgery

  NCT04902625· Phase 4· Zuyderland Medisch Centrum Stichting· Source

• Active, not recruiting

  ABTECT - Maintenance

  NCT05535946· Phase 3· Abivax S.A.· Source

• Recruiting

  What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?

  NCT04436978· Phase 4· St. Antonius Hospital· Source

• Not yet recruiting

  Avelumab Short Maintenance Trial

  2024-512975-11-01· Phase 4· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source

• Active, not recruiting

  Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM

  NCT03673826· Phase 2· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Recruiting

  DRUP trial

  NCT02925234· Phase 2· Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting· Source

• Active, not recruiting

  Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer

  NCT01898117· Phase 2· The Netherlands Cancer Institute· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Idiopathic pulmonary fibrosis6 recruiting
• Obesity6 recruiting
• Stroke4 recruiting
• Atrial fibrillation3 recruiting
• Heart failure2 recruiting
• Lung cancer2 recruiting
• Ankylosing spondylitis1 recruiting
• Asthma1 recruiting
• Bladder cancer1 recruiting
• Colorectal cancer1 recruiting
• COPD1 recruiting
• Coronary artery disease1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Hodgkin lymphoma1 recruiting
• Melanoma1 recruiting
• Multiple myeloma1 recruiting
• Prostate cancer1 recruiting
• Sarcoidosis1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  A Patient guided dose reduction strategy of tyrosine kinase inhibitors in chronic myeloid leukaemia: RODEO study

  2024-516511-24-00· Phase 4· Stichting Radboud universitair medisch centrum· Source

• Recruiting

  Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis

  2023-504358-36-00· Phase 3· Sanofi-Aventis Recherche & Developpement· Source

• Active, not recruiting

  A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC

  2023-504753-12-00· Phase 3· Glaxosmithkline Research & Development Limited· Source

• Completed

  A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)

  2023-506185-31-00· Phase 2/3· Pliant Therapeutics Inc.· Source

• Completed

  A proof of concept and dose-finding study of XXB750 in patients with heart failure

  2023-504678-39-00· Phase 2· Novartis Pharma AG· Source

• Completed

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

  NCT06040086· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission

  NCT05622708· Phase 4· Novartis Pharmaceuticals· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

  NCT05507203· Phase 3· Abivax S.A.· Source

• Active, not recruiting

  A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

  NCT05450692· Phase 3· AstraZeneca· Source

• Completed

  Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

  NCT05255991· Phase 3· United Therapeutics· Source

• Completed

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

  NCT05166889· Phase 3· AstraZeneca· Source

• Completed

  The efficacy and safety of two doses of CHF6001 DPI as add-on to maintenance COPD triple therapy

  NCT04636814· Phase 3· Chiesi Farmaceutici S.p.A.· Source

• Completed

  The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD)

  NCT04636801· Phase 3· Chiesi Farmaceutici S.p.A.· Source

• Completed

  A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer

  NCT04746924· Phase 3· Beigene Ltd.· Source

• Completed

  REDUAL PCI Real Life Registry

  NCT04688723· Phase 4· Zuyderland Medisch Centrum Stichting· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Amgen· Source

• Completed

  Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)

  NCT02504372· Phase 3· Merck Sharp & Dohme LLC· Source